Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Early Phase 1
2(66.7%)
N/A
1(33.3%)
3Total
Early Phase 1(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01139593Completed

A Trial Comparing Qam With Qpm Dosing in Assisted Reproductive Technologies (ART)

Role: lead

NCT01129830Early Phase 1Terminated

The Effect of DHEA on Markers of Ovarian Reserve in Women With Diminished Ovarian Reserve

Role: lead

NCT00867659Not ApplicableCompleted

The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors

Role: lead

NCT01129947Early Phase 1Withdrawn

The Use of DHEA in Women With Premature Ovarian Failure

Role: lead

NCT00740025Completed

Once Daily vs Twice Daily Administration of Gonadotropins in Assisted Reproductive Technologies (ART)

Role: lead

All 5 trials loaded